Orally inhaled & nasal drugs
FDA's Orally Inhaled & Nasal Drugs Subcommittee of the Pharmaceutical Science Advisory Committee will discuss dose response for locally-acting nasal sprays and aerosols July 17. The subcommittee's recommendations will be discussed at a July 19 meeting of the Pharmaceutical Science Advisory Committee
You may also be interested in...
FDA's risk-based chemistry, manufacturing & controls review proposal should include a list of high-risk drugs, Pharmaceutical Research & Manufacturers of America said.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011